康芝药业
(300086)
| 流通市值：27.19亿 | | | 总市值：28.08亿 |
| 流通股本：4.41亿 | | | 总股本：4.55亿 |
| 利润表 |
| 报告期 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
| 营业总收入 | 96,573,833.91 | 466,122,703.87 | 326,382,078.2 | 232,448,515.1 |
| 营业总成本 | 105,357,588.5 | 650,931,951.28 | 454,805,398.28 | 302,106,524.19 |
| 其他经营收益 | | | | |
| 营业利润 | -6,462,492.15 | -257,307,939.33 | -111,905,166.66 | -60,689,697.11 |
| 利润总额 | -6,387,974.8 | -259,472,149.65 | -111,836,688.1 | -60,618,864.83 |
| 净利润 | -12,139,036.55 | -234,028,867.48 | -98,123,635.62 | -55,108,349.75 |
| 每股收益 | | | | |
| 其他综合收益 | - | 14,335,824.51 | - | - |
| 综合收益总额 | -12,139,036.55 | -219,693,042.97 | -98,123,635.62 | -55,108,349.75 |
| 资产负债表 |
| 报告期 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
| 流动资产: | | | | |
| 流动资产合计 | 268,806,788.96 | 304,478,619.13 | 310,264,598.08 | 336,300,298.71 |
| 非流动资产: | | | | |
| 非流动资产合计 | 1,468,423,995.3 | 1,486,526,147.35 | 1,569,157,899.79 | 1,569,158,432.29 |
| 资产总计 | 1,737,230,784.26 | 1,791,004,766.48 | 1,879,422,497.87 | 1,905,458,731 |
| 流动负债: | | | | |
| 流动负债合计 | 542,487,879.51 | 583,491,864.39 | 486,804,303.2 | 477,743,568.98 |
| 非流动负债: | | | | |
| 非流动负债合计 | 285,685,289.01 | 286,297,087.7 | 343,435,010.02 | 341,928,213.49 |
| 负债合计 | 828,173,168.52 | 869,788,952.09 | 830,239,313.22 | 819,671,782.47 |
| 所有者权益(或股东权益): | | | | |
| 归属于母公司股东权益合计 | 887,940,580.06 | 899,709,487.23 | 1,025,298,787.71 | 1,061,417,042.8 |
| 股东权益合计 | 909,057,615.74 | 921,215,814.39 | 1,049,183,184.65 | 1,085,786,948.53 |
| 负债和股东权益合计 | 1,737,230,784.26 | 1,791,004,766.48 | 1,879,422,497.87 | 1,905,458,731 |
| 现金流量表 |
| 报告期 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
| 经营活动产生的现金流量: | | | | |
| 经营活动现金流入小计 | 112,892,773.59 | 728,183,776.89 | 516,110,551.58 | 384,567,604.3 |
| 经营活动现金流出小计 | 135,822,302.81 | 606,941,712.51 | 458,931,927.15 | 318,215,108.54 |
| 经营活动产生的现金流量净额 | -22,929,529.22 | 121,242,064.38 | 57,178,624.43 | 66,352,495.76 |
| 投资活动产生的现金流量: | | | | |
| 投资活动现金流入小计 | 460 | 84,366.68 | 84,366.68 | 1,666.68 |
| 投资活动现金流出小计 | 3,891,509.94 | 92,172,653.35 | 84,065,451.44 | 78,874,898.36 |
| 投资活动产生的现金流量净额 | -3,891,049.94 | -92,088,286.67 | -83,981,084.76 | -78,873,231.68 |
| 筹资活动产生的现金流量: | | | | |
| 筹资活动现金流入小计 | 10,091,307 | 252,925,908.4 | 180,970,998.93 | 113,826,220.68 |
| 筹资活动现金流出小计 | 25,728,760.15 | 330,851,623 | 249,388,891.91 | 167,019,127.37 |
| 筹资活动产生的现金流量净额 | -15,637,453.15 | -77,925,714.6 | -68,417,892.98 | -53,192,906.69 |
| 汇率变动对现金及现金等价物的影响 | -24,534.99 | -22,596.7 | -12,884.07 | -13,875.16 |
| 现金及现金等价物净增加额 | -42,482,567.3 | -48,794,533.59 | -95,233,237.38 | -65,727,517.77 |
| 期末现金及现金等价物余额 | 17,269,378.96 | 59,382,790.81 | 17,952,248.56 | 47,457,968.17 |
| 补充资料: | | | | |
| 现金及现金等价物的净增加额 | - | -48,794,533.59 | - | -65,727,517.77 |